Literature DB >> 18705423

Ophthalmic manifestations of multiple myeloma.

A E Omoti1, C E Omoti.   

Abstract

BACKGROUND: The ophthalmic manifestations of multiple myeloma can be seen in practically every ocular structure. Ocular findings may be the first manifestations of the disease. It may also occur as one of the extramedullary manifestations of the disease or as the first sign of insufficient chemotherapy. Multiple myeloma may cause ocular pathology by direct infiltration or as extramedullary plasmacytomas resulting in displacement or compression of tissues, by causing hyperviscosity syndrome, and by immunoglobulin light chain deposition in ocular tissues.
OBJECTIVE: To outline the ophthalmic manifestations of multiple myeloma.
METHODS: Information about multiple myeloma and ophthalmic manifestations was obtained from original journal articles, review articles, case reports and standard postgraduate textbooks.
RESULTS: Ophthalmic manifestations include proptosis, diplopia, lid ecchymosis, xanthomatosis, conjunctival and corneal crystalline and non-crystalline deposits, scleritis, episcleritis, secondary glaucoma, ciliary body cysts, ciliochoroidal effusion, uveal plasmacytoma, hyperviscosity retinopathy, retinal vasculitis, detachment of sensory retina and retinal pigment epithelium, and neuro-ophthalmic manifestations.
CONCLUSIONS: In multiple myeloma, it is necessary to take a closer look at the ophthalmic manifestations, both because of their local morbidity and because they might act as a reservoir for proliferation of myeloma cells and eventual systemic relapse. Early detection may permit safer and effective treatment. All patients with multiple myeloma should thus undergo thorough ophthalmic examination at the time of initial diagnosis and during follow-up.

Entities:  

Mesh:

Year:  2007        PMID: 18705423     DOI: 10.4314/wajm.v26i4.28324

Source DB:  PubMed          Journal:  West Afr J Med        ISSN: 0189-160X


  12 in total

1.  Oculomotor Nerve Palsy as a Rare Presentation and First Sign of Multiple Myeloma.

Authors:  Bijnya Birajita Panda; Sucheta Parija; Jyotiranjan Mallick; Susanta Pujahari
Journal:  J Clin Diagn Res       Date:  2016-05-01

2.  Anticancer Role of PPARgamma Agonists in Hematological Malignancies Found in the Vasculature, Marrow, and Eyes.

Authors:  P J Simpson-Haidaris; S J Pollock; S Ramon; N Guo; C F Woeller; S E Feldon; R P Phipps
Journal:  PPAR Res       Date:  2010-02-28       Impact factor: 4.964

3.  Multiple myeloma and diabetes.

Authors:  Zeinab A Issa; Mira S Zantout; Sami T Azar
Journal:  ISRN Endocrinol       Date:  2011-11-17

Review 4.  Clinical challenges: myeloma and concomitant type 2 diabetes.

Authors:  Yasar Albushra Abdul Rahiem Ahmed; Awad Eltayeb
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2013

5.  Clinical challenges: Myeloma and concomitant type 2 diabetes.

Authors:  Mohamed Ahmed Ali; Yasar A Ahmed; Abubaker Ibrahim
Journal:  South Asian J Cancer       Date:  2013-10

6.  The Incidence of Senile Cataract and Glaucoma is Increased in Patients with Plasma Cell Dyscrasias: Etiologic Implications.

Authors:  Kari Hemminki; Asta Försti; Raimo Tuuminen; Otto Hemminki; Hartmut Goldschmidt; Kristina Sundquist; Jan Sundquist; Xinjun Li
Journal:  Sci Rep       Date:  2016-06-22       Impact factor: 4.379

7.  Retinal pigment epithelial detachments and tears, and progressive retinal degeneration in light chain deposition disease.

Authors:  Leigh H Spielberg; John R Heckenlively; Anita M Leys
Journal:  Br J Ophthalmol       Date:  2013-02-05       Impact factor: 4.638

8.  Multiple myeloma of the orbit.

Authors:  Mona Hassan; Zaid Alirhayim; Laila Sroujieh; Syed Hassan
Journal:  Case Rep Ophthalmol Med       Date:  2012-11-06

9.  Efficacy of lenalidomide in association with cyclophosphamide and dexamethasone in multiple myeloma patient with bilateral retro-orbital localisation.

Authors:  S Felici; N Villivà; G Balsamo; A Andriani
Journal:  Ecancermedicalscience       Date:  2013-07-10

10.  Right orbital edema masquerading a hematologic malignancy.

Authors:  Andrew C Tiu; Vivian Arguello-Guerra; Gabor Varadi
Journal:  SAGE Open Med Case Rep       Date:  2018-01-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.